Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

temporal arteritis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

temporal arteritis

MONDO:0008538

Also known as:Giant Cell ArteritisHorton diseaseHorton's disease

Find Clinical TrialsTrials

Overview

A large vessel vasculitis predominantly involving the arteries originating from the aortic arch and especially the extracranial branches of the carotid arteries.

GeneticsAutosomal dominant

Treatments3 FDA approved, newest 2024

Clinical Trials52 registered · 34 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Joint stiffness, Weight loss, Fever, and Anorexia and others; and common findings: Elevated erythrocyte sedimentation rate, Visual impairment, Ophthalmoparesis, and Depression and others. 71 total HPO annotations.

Organ System	Phenotype Count	Example Features
Brain and nerves	10	Headache, Cerebral ischemia, Fatigue

Diagnosis

Biomarker and diagnostic research for temporal arteritis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

3 FDA-approved treatments are available for temporal arteritis, including UPADACITINIB (RINVOQ, approved 2019), TOCILIZUMAB-AAZG (TYENNE, approved 2024), and TRIAMCINOLONE ACETONIDE (TRIESENCE, approved 2007). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Prognosis

Phenotype severity distribution: 10 very common features, 15 common features.

Estimated prevalence: 1-5 in 10,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

52 clinical trials registered, 34 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and procedural interventions. Pipeline includes 3 PHASE4, 6 PHASE3, 5 PHASE2. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07084480](https://clinicaltrials.gov/study/NCT07084480)

Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:187360

Orphanet

European rare disease database

Orphanet:397

GARD

Genetic and Rare Diseases Info Center

GARD:9615

Questions for Your Care Team

→What are the benefits and potential side effects of RINVOQ for managing temporal arteritis?
→Are any of the 52 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
mavrilimumab	mavrilimumab	Kiniksa Pharmaceuticals, GmbH	2020	—	Withdrawn
Abatacept	Abatacept	Bristol-Myers Squibb Research & Development	2017	—	Designated
infliximab	infliximab	Centocor, Inc.	2003	—	Withdrawn

Research Type	Count	% of Total
Research summaries	52	37%
Disease patterns and progression	30	21%
Patient case studies	28	20%
Testing and diagnosis research	13	9%
Other research	9	6%
Laboratory research	7	5%
Clinical study results	3	2%

Kisho

temporal arteritis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

temporal arteritis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications